Pure Global

Irregular Rhythm Notification Feature - India CDSCO Medical Device Registration

Irregular Rhythm Notification Feature is a medical device registered with India's Central Drugs Standard Control Organization (CDSCO) under UID IMP/MD/2022/000754_2ae4c1abcd87e3400ffd1f172863b0a4_03181e068806940e9b3323e36449497d. This device is marketed under the brand name Atrial Fibrillation History Feature. The license holder is M/S ASIA ACTUAL INDIA (OPC) PVT. LTD., and it is classified as Device Class Class B. The approving authority is CDSCO.

This page provides comprehensive regulatory information including complete registration details, license holder information, device classification, and related products. Pure Global AI offers free access to 71,807+ India medical device registrations, helping global MedTech companies identify partners, analyze markets, and discover business opportunities efficiently.

Free Database
Powered by Pure Global AI
CDSCO Registered
Class Class B
Irregular Rhythm Notification Feature
UID: IMP/MD/2022/000754_2ae4c1abcd87e3400ffd1f172863b0a4_03181e068806940e9b3323e36449497d

Brand Name

Atrial Fibrillation History Feature

Device Class

Class B

Approving Authority

CDSCO

Product Information

The Irregular Rhythm Notification Feature is a software-only mobile medical application that is intended to be used with the Apple Watch. The feature analyzes pulse rate data to identify episodes of irregular heart rhythms suggestive of atrial fibrillation (Atrial Fibrillation History Feature) and provides a notification to the user. The feature is intended for over-the-counter (Atrial Fibrillation History Feature) use. It is not intended to provide a notification on every episode of irregular rhythm suggestive of AFib and the absence of a notification is not intended to indicate no disease process is present; rather the feature is intended to opportunistically surface a notification of possible AFib when sufficient data are available for analysis. These data are only captured when the user is still. Along with the userโ€™s risk factors, the feature can be used to supplement the decision for AFib screening. The feature is not intended to replace traditional methods of diagnosis or treatment. The feature has not been tested for and is not intended for use in people under 22 years of age. It is also not intended for use in individuals previously diagnosed with AFib

Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing